Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousand... (ailto:journalisthelp@thenewsmarket.com j...)

Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousands of Women

Date:12/18/2007

ailto:journalisthelp@thenewsmarket.com">journalisthelp@thenewsmarket.com

'More Positive Conversations' global survey

The 'More Positive Conversations' survey was conducted online and via telephone interviews by Harris Interactive on behalf of AstraZeneca. The survey involved 1,062 physicians and patients from France, Germany, Italy, the United Kingdom and the US.

AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.

Arimidex (anastrozole) is a trademark, the property of the AstraZeneca group of companies.

References

1. The ATAC Trialist Group -Effect of anastrozole and tamoxifen as

adjuvant treatment for early-stage breast cancer; 100 month analysis of

the ATAC trial -published online, Lancet Oncology Saturday 15 December

2. Forbes J, on behalf on the ATAC Trialist's Group. ATAC: 100 month

median follow-up shows continued superior efficacy and no excess

fracture risk for anastrozole compared with tamoxifen after treatment

completion. Abstract no 41. San Antonio Breast Cancer Symposium 2007.

3. Parkin, D.M., E. Laara, and C.S. Muir, Estimates of the worldwide

frequency of sixteen major cancers in 1980. Int J Cancer, 1988. 41(2):

p. 184-97.